Symptom Management After Breast Cancer Surgery
This study is ongoing, but not recruiting participants.
Sponsor:
University of California, San Francisco
Information provided by (Responsible Party):
University of California, San Francisco
ClinicalTrials.gov Identifier:
NCT00686127
First received: May 27, 2008
Last updated: March 21, 2012
Last verified: March 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This trial is part of a larger, longitudinal study of symptoms that occur in the breast surgical scar area and/or ipsilateral arm following breast cancer surgery. Women who develop pain in the breast scar area or ipsilateral arm will be randomized to a placebo patch or a lidocaine patch that they will wear on a daily basis for 12 weeks. We hypothesize that women who wear the lidocaine patch will report a decrease in pain and decreased interference with function compared to women who wear the placebo patch.
| Condition | Intervention | Phase |
|---|---|---|
|
Neuropathic Pain Postmastectomy Pain |
Drug: Lidoderm patch Drug: Placebo patch |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Double Blind (Subject, Outcomes Assessor) Primary Purpose: Supportive Care |
| Official Title: | A Randomized, Double-Blind, Placebo-Controlled Trial (RDBPCT) of the Effectiveness of the Lidocaine Patch in the Management of Neuropathic Pain After Breast Cancer Surgery |
Resource links provided by NLM:
Further study details as provided by University of California, San Francisco:
Primary Outcome Measures:
- pain intensity [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- pain interference with function [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 190 |
| Study Start Date: | September 2003 |
| Estimated Study Completion Date: | December 2013 |
| Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: 1
Lidocaine patch
|
Drug: Lidoderm patch
One patch is changed every twenty-four hours
Other Name: Lidoderm
|
|
Placebo Comparator: 2
Placebo patch
|
Drug: Placebo patch
Patch is changed every 24 hours
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Adult women >18 years who develop neuropathic pain in the breast scar area and/or ipsilateral arm following breast cancer surgery
- Has a healed incision(s)
- Has no recurrent disease in the painful area
- Is able to read, write and understand English
Exclusion Criteria:
- Presence of another type of pain that is more severe than the neuropathic pain
- Use of an opioid analgesic of greater than 60 mg codeine/day
- Is actively trying to become pregnant
- Has a medical contraindication to the use of lidocaine
- Has an allergy to lidocaine
- Is taking a coanalgesic for neuropathic pain.
Contacts and Locations
More Information
No publications provided
| Responsible Party: | University of California, San Francisco |
| ClinicalTrials.gov Identifier: | NCT00686127 History of Changes |
| Other Study ID Numbers: | Breast Pain, CA107091 |
| Study First Received: | May 27, 2008 |
| Last Updated: | March 21, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by University of California, San Francisco:
|
breast cancer neuropathic pain topical lidocaine |
postmastectomy pain breast symptoms breast pain |
Additional relevant MeSH terms:
|
Breast Neoplasms Neuralgia Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Pain Neurologic Manifestations Nervous System Diseases Peripheral Nervous System Diseases Neuromuscular Diseases Signs and Symptoms |
Lidocaine Anesthetics, Local Anesthetics Central Nervous System Depressants Physiological Effects of Drugs Pharmacologic Actions Sensory System Agents Peripheral Nervous System Agents Central Nervous System Agents Therapeutic Uses Anti-Arrhythmia Agents Cardiovascular Agents |
ClinicalTrials.gov processed this record on May 22, 2013